Kesimpta Európska únia - slovenčina - EMA (European Medicines Agency)

kesimpta

novartis ireland ltd - ofatumumab - roztrúsená skleróza, recidivujúce-odosielajúcej - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Tibsovo Európska únia - slovenčina - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastické činidlá - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Equip WNV (previously Duvaxyn WNV) Európska únia - slovenčina - EMA (European Medicines Agency)

equip wnv (previously duvaxyn wnv)

zoetis belgium sa - inaktivovaného vírusu west nile, kmeňa vm-2 - imunologické pomôcky pre koňovité - kone - na aktívnu imunizáciu koní vo veku šesť mesiacov alebo starších proti vírusu west-nile-vírusu znížením počtu virémických koní.

Spevigo Európska únia - slovenčina - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - svrab - imunosupresíva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Rybrevant Európska únia - slovenčina - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Qutenza Európska únia - slovenčina - EMA (European Medicines Agency)

qutenza

grunenthal gmbh - capsaicin - neuralgia - anestetiká - liek qutenza je indikovaný na liečbu periférnej neuropatickej bolesti u dospelých buď samostatne alebo v kombinácii s inými liekmi na bolesť.

Elzonris Európska únia - slovenčina - EMA (European Medicines Agency)

elzonris

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastické činidlá - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).